Pfizer enters Enodia pact: Guggenheim targets Pfizer stock at USD 31

Published on 10/14/2026 at 10:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 15.03 billion, up 1.00 percent operationally. Pfizer stock costs EUR 25.41 on October 14, 2026 after the EUR 25.32 Xetra close.

Enodia pact and Pfizer outlook

Pfizer entered the Enodia collaboration on October 13, 2026, with potential value above USD 500 million.
Second-quarter 2026 revenue reached USD 15.03 billion, with 1.00 percent operational growth.
Pfizer stock traded at EUR 25.41 at 10:08 a.m. CEST on October 14, 2026, 0.36 percent above the Xetra close of October 13, 2026.

Extreme Nahaufnahme unbeschrifteter weißer Tabletten und Kapseln, Symbolbild für Pfizer Inc — Makroaufnahme unbeschrifteter Tabletten und Kapseln veranschaulicht das Kerngeschäft von Pfizer Inc., ISIN US7170811035, Pharmaindustrie, Illustration mit AI erstellt.

Pfizer Inc. (US7170811035) was trading at EUR 25.41 at Lang & Schwarz on October 14, 2026 at 10:08 a.m. CEST, 0.36 percent above the Xetra close of EUR 25.32 on October 13, 2026. On October 13, Pfizer entered a research and licensing pact with Enodia Therapeutics that could be worth more than USD 500 million, while Guggenheim reiterated a Buy rating and a USD 31.00 target for Pfizer stock, as Investing.com reported.

What does the pact add?

European Biotechnology reported on October 13, 2026, that the agreement covers small-molecule therapies targeting the Sec61 translocon. Enodia will lead discovery activities, while Pfizer will handle clinical, manufacturing, regulatory and commercial work after the research phase.

The potential value exceeds USD 500 million and includes an upfront payment, research and development milestones, sales milestones and tiered royalties. The targets remain undisclosed, so the deal is strategically material but does not yet provide a product-level revenue forecast.

Pfizer results set the baseline

In the second quarter of 2026, Pfizer reported USD 15.03 billion in revenue and a GAAP loss per share of USD 0.04. Its adjusted diluted earnings per share was USD 0.77, while operational revenue growth reached 1.00 percent year over year, according to the Yahoo Finance transcript of the August 4, 2026 earnings call.

Management raised the midpoint of full-year 2026 revenue guidance by USD 500 million to a range of USD 60.5 billion to USD 62.5 billion and reaffirmed adjusted diluted earnings-per-share guidance of USD 2.80 to USD 3.00. Guggenheim expects third-quarter 2026 revenue of USD 16.16 billion against Visible Alpha consensus of USD 15.90 billion, a USD 0.26 billion comparison that places the upcoming report above consensus in the firm's model.

Three dated Pfizer developments

On August 4, 2026, Pfizer reported second-quarter revenue of USD 15.03 billion and adjusted diluted earnings per share of USD 0.77. On October 8, 2026, Cantor Fitzgerald raised its target from USD 27.00 to USD 28.00 while retaining a Neutral rating, according to MarketBeat. On October 13, 2026, the Enodia pact set a potential deal value above USD 500 million.

When are the next dates?

Pfizer's investor calendar lists a conference call with analysts for November 3, 2026, as shown on the Pfizer website. MarketBeat reported that the quarterly dividend is scheduled for payment on December 7, 2026.

Stock trades above Xetra close

At Lang & Schwarz, Pfizer stock was trading at EUR 25.41 on October 14, 2026 at 10:08 a.m. CEST, 0.36 percent above the Xetra close of EUR 25.32 on October 13, 2026. The primary listing is on the NYSE, where the stock was last quoted at USD 28.37 on October 13, 2026 at 8:02 p.m. UTC, with a 52-week range of USD 23.62 to USD 29.21 and market capitalization of USD 161.7 billion.

The further course of trading is shown by the continuously updated real-time quote of Pfizer stock.